XGN earnings analysis
What we found in XGN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Exagen delivered a strong Q2 operating improvement: revenue increased 15.9% to $19.941 million, gross margin rose 90 basis points to 61.3%, and operating loss narrowed to $1.722 million. Volume growth, a $446 AVISE CTD ASP, and higher pharma-services revenue supported the result, while six-month operating cash burn improved by $7.127 million year over year. The investment case remains balanced by ongoing losses, $1.201 million of quarterly interest expense, payor/reimbursement uncertainty, and substantial reliance on AVISE CTD; the filing states there were no material changes to risk factors from the 2025 annual report.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue growth accelerated to 15.9%
- Q2 revenue rose 15.9% year over year to $19.941 million from $17.202 million and increased 15.2% sequentially from implied Q1 revenue of $17.306 million. Growth was driven by approximately 11% higher AVISE CTD test volume, a 4%/$18 ASP increase to $446, and pharma-services revenue rising to $1.0 million from $0.3 million.
- Gross margin expanded 90 basis points
- Gross margin expanded to 61.3% from 60.4% a year earlier and 59.0% in Q1 2026. Gross profit increased $1.822 million to $12.217 million, outpacing the $0.917 million increase in cost of revenue.
- Operating loss narrowed materially
- Operating loss narrowed to $1.722 million from $2.630 million a year ago, improving operating margin to -8.6% from -15.3%; this also improved from an implied $3.414 million Q1 operating loss and -19.7% margin. Net loss narrowed $1.243 million to $3.196 million.
- Cash burn improved despite modest capex
- Six-month operating cash use improved to $6.429 million from $13.556 million. Capital expenditures were $0.771 million, or approximately 2.1% of $37.247 million of six-month revenue, implying approximately $7.200 million of six-month free-cash-flow use.
- Liquidity supports near-term runway
- Liquidity stood at $24.6 million of cash and cash equivalents at June 30, 2026; management also has up to $40.0 million available under the Perceptive term loan if revenue and other conditions are met. Cash declined $7.632 million in the first six months, but management expects the Q1 claims-related working-capital trend to continue reversing during the remaining two quarters.
- Pipeline provides longer-term expansion path
- Pipeline development continues: management expects its first Myositis offering to launch in 2027, while SLE Disease Activity is in clinical validation and RA Disease Activity has a validation cohort procured. AVISE CTD supplied 90% of six-month revenue, underscoring the importance of broadening the portfolio.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Losses and accumulated deficit remain high
- The company remains unprofitable, reporting a $3.196 million Q2 net loss and a $321.4 million accumulated deficit as of June 30, 2026. Management expects additional losses in future periods.
- Debt costs and conditional liquidity capacity
- Interest expense increased to $1.201 million in Q2 from $1.124 million, while the Perceptive facility requires at least $3.0 million of unrestricted cash. The additional $40.0 million facility capacity is conditional on specified revenue levels and other conditions.
- Payor coverage risk concentrated in AVISE CTD
- Revenue concentration and reimbursement uncertainty remain material: AVISE CTD represented 90% of six-month revenue, while the $840.65 Medicare PLA price for AVISE Lupus does not assure coverage. The company states that commercial-payor denials tied to unfavorable medical policies are expected to persist.
- Input costs and tariffs could pressure margin
- Cost pressures could constrain margin progress: Q2 cost of revenue rose $0.917 million, including $0.3 million for materials and supplies, while added CTD biomarkers have increased cost per test year over year. Management also cites potential tariffs on imported reagents, including supplies sourced from Germany.
- New lease adds fixed-cost commitment
- A new Carlsbad office lease beginning May 1, 2027 carries approximately $0.6 million of annual rent, escalating 3% annually through July 2030, plus the company's share of building operating and tax expenses.
What they reported.
What the company itself reported, taken out of the document.
- Gross margin
- 61.3%
- Operating margin
- -8.6%
What they said about what is next.
The 10-Q contains no explicit quantitative revenue or EPS guidance. Management stated that SG&A and R&D may increase moderately in absolute dollars near term, while declining as a percentage of revenue; it expects existing cash and anticipated revenue to fund requirements for at least 12 months from filing.
The filing reads better than the one before it.
What came before.
- 10-Q · May 11, 2026
- Exagen Inc. reported Q1 2026 earnings with a revenue of $17.3 million, exceeding estimates and reflecting an 11.7% increase year-over-year. The company continues to incur losses, reporting a net loss of $4 million,…
- 10-K · March 10, 2026
- Exagen reported record 2025 revenue of $66.6 million, up approximately 19.7% versus 2024, driven by ~11% test volume growth and ~7% ASP expansion. The business remains highly concentrated in its flagship AVISE® CTD test…
- 10-Q · July 29, 2025
- Exagen reported Q2 revenue of $17,202,000, up $2,138,000 (≈14.2%) versus $15,064,000 in Q2 2024, with gross margin of $10,395,000 (60.4%). The company widened its GAAP net loss to $(4,439,000) (EPS $(0.21)) for the…
- 10-Q · May 5, 2025
- Exagen reported quarterly revenue of $15,498,000 (up from $14,415,000 a year ago) and GAAP net loss per share of $(0.20) (vs $(0.19) prior year). Gross margin dollars were $9,123,000 (58.9%) and loss from operations was…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing XGN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever